Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Antibody therapies are a large and rapidly evolving class of drugs that can provide significant health benefits. Alfa Cytology offers therapeutic antibody development services, providing clients with different forms of therapeutic antibodies for breast cancer treatment.
Breast cancer (BC) is a highly heterogeneous malignant tumor occurring in breast epithelial tissue, which is more common in women. The systemic treatment of BC has initially formed a mature system including chemotherapy, targeted therapy, endocrine therapy, neoadjuvant therapy, surgery, and immunotherapy. Antibody-based therapeutic strategies have emerged as an established treatment option for bladder cancer over the past decade.
Fig.1 Monoclonal antibodies in breast cancer. (Behl A., et al. 2023)
| Target | NCT | Therapeutics | Phase |
| PD-1/PD-L1 | NCT05422794 | Pembrolizumab | |
| NCT03971409 | Avelumab | ||
| NCT03281954 | Atezolizumab | ||
| NCT02826434 | Durvalumab | ||
| CTLA-4 | NCT04606472 | SI-B003 (a CTLA-4/PD-1 bispecific antibody) | |
| NCT05620134 | JK08 (CTLA-4 targeting IL-15 antibody fusion protein) |
Alfa Cytology is equipped with extensive expertise in this field and is committed to assisting you and your teams in developing safe and efficacious therapeutic antibodies with utmost efficiency. We offer a one-stop service for the development of therapeutic antibodies for the treatment of breast cancer.
Therapeutic Monoclonal Antibody Development Platform
Therapeutic Antibody Fragment Development Platform
Therapeutic Bispecific Antibody (BsAb) Development Platform
Antibody-drug Conjugates Development Platform
Bispecific Antibody-drug Conjugates (BsADCs) Development Platform
Breast Cancer Single-domain Antibody Development Platform
As a trusted partner in therapeutic antibody generation, Alfa Cytology is fully dedicated to contributing to the success of our customers' breast cancer therapeutic projects. We are committed to supporting your therapeutic antibody discovery project and gain access to the most comprehensive solution for developing your antibody drug candidate. If you are interested in our service, please contact us.
Reference